- Home
- INSP vs ARQT Comparison
INSP vs ARQT Comparison
Compare INSP & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSP
- ARQT
- Stock Information
- Founded
- INSP 2007
- ARQT 2016
- Country
- INSP United States
- ARQT United States
- Employees
- INSP N/A
- ARQT N/A
- Industry
- INSP Medical/Dental Instruments
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- INSP Health Care
- ARQT Health Care
- Exchange
- INSP Nasdaq
- ARQT Nasdaq
- Market Cap
- INSP 3.8B
- ARQT 3.3B
- IPO Year
- INSP 2018
- ARQT 2020
- Fundamental
- Price
- INSP $115.12
- ARQT $30.30
- Analyst Decision
- INSP Buy
- ARQT Strong Buy
- Analyst Count
- INSP 16
- ARQT 7
- Target Price
- INSP $139.40
- ARQT $22.17
- AVG Volume (30 Days)
- INSP 1.3M
- ARQT 3.3M
- Earning Date
- INSP 11-03-2025
- ARQT 10-28-2025
- Dividend Yield
- INSP N/A
- ARQT N/A
- EPS Growth
- INSP 34.77
- ARQT N/A
- EPS
- INSP 1.48
- ARQT N/A
- Revenue
- INSP $882,622,000.00
- ARQT $317,929,000.00
- Revenue This Year
- INSP $14.83
- ARQT $85.27
- Revenue Next Year
- INSP $14.44
- ARQT $30.70
- P/E Ratio
- INSP $60.88
- ARQT N/A
- Revenue Growth
- INSP 16.81
- ARQT 129.21
- 52 Week Low
- INSP $70.77
- ARQT $10.03
- 52 Week High
- INSP $216.01
- ARQT $30.01
- Technical
- Relative Strength Index (RSI)
- INSP 79.74
- ARQT 74.49
- Support Level
- INSP $81.79
- ARQT $27.08
- Resistance Level
- INSP $92.01
- ARQT $28.96
- Average True Range (ATR)
- INSP 4.47
- ARQT 1.64
- MACD
- INSP 2.14
- ARQT 0.43
- Stochastic Oscillator
- INSP 98.93
- ARQT 93.98
About INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.